Novel glycosyl derivatives of dopamine and L-dopa (I-IV) are synthesized in order to overcome the problem of blood-brain barrier low permeability of dopamine and of low bioavailability of its precursor L-dopa. Esters synthesized link dopamine and L-dopa, by a succinyl linker, to C-3 position of glucose (I and II) and to C-6 of galactose (II and IV). The chemical and enzymatic stabilities of esters synthesized were evaluated in order to determine both their stability in aqueous medium and their feasibility in undergoing enzymatic cleavage by rat plasma to regenerate the original drug. Furthermore, we have shown the central effects of esters I-IV on classic dopaminergic models, such as morphine induced locomotion and reserpine-induced hypolocomotion. From the result obtained compounds I-IV appeared moderately stable in a pH 7.4 buffered solution and in rat plasma. Furthermore, pharmacological studies showed that both dopamine derivatives (I and II) were equiactive in reversing reserpine-induced hypolocomotion in rats, and both were more active than L-dopa or ester III and IV, while II and III were more potent in reducing morphine-induced locomotion than I and IV. The minimal vascular effects of these derivatives allow us to underline the possibility to use them in pathologies, such as Parkinson disease, characterised by an evident decreasing of dopamine concentration in the brain.
Paracetamol has been one of the most
commonly used and prescribed
analgesic drugs for more than a hundred years. Despite being generally
well tolerated, it can result in high liver toxicity when administered
in specific conditions, such as overdose, or in vulnerable individuals.
We have synthesized and characterized a paracetamol galactosylated
prodrug (PARgal) with the aim of improving both the pharmacodynamic
and pharmacological profile of paracetamol. PARgal shows a range of
physicochemical properties, solubility, lipophilicity, and chemical
stability at differing physiological pH values and in human serum.
PARgal could still be preclinically detected 2 h after administration,
meaning that it displays reduced hepatic metabolism compared to paracetamol.
In overdose conditions, PARgal has not shown any cytotoxic effect
in in vitro analyses performed on human liver cells.
Furthermore, when tested in an animal pain model, PARgal demonstrated
a sustained analgesic effect up to the 12th hour after
oral administration. These findings support the use of galactose as
a suitable carrier in the development of prodrugs for analgesic treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.